Evidence map›Paper›PMID 42787631›Full record

ArticleAmerican journal of nuclear medicine and molecular imaging2026

A functional view on the enhanced therapeutic effects of the control-released recombinant human endostatin.

Xuyu Zhang, Kun Zhao, Kaining Yang, Xiao Li, Fengcai Li, Jiahua Zhou, Ni Wang, Yanli Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xuyu ZhangBaoding Second Central Hospital Baoding 072750, Hebei, China.
Kun ZhaoBaoding Second Central Hospital Baoding 072750, Hebei, China.
Kaining YangBaoding Second Central Hospital Baoding 072750, Hebei, China.
Xiao LiShanghai Institute of Applied Physics, Chinese Academy of Science Shanghai 201800, China.
Fengcai LiBaoding Second Central Hospital Baoding 072750, Hebei, China.
Jiahua ZhouDepartment of Medical Oncology, Shanghai Jiangong Hospital Shanghai 200083, China.
Ni WangShanghai Institute of Applied Physics, Chinese Academy of Science Shanghai 201800, China.
Yanli WangBaoding Second Central Hospital Baoding 072750, Hebei, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recombinant human endostatin (RHE) has been applied in treating non-small cell lung cancer via inhibiting tumor neovascularization. In this study, a controlled release of RHE was proposed and manifested in a fluorescent view. In a mice model with NSCLC xenografts, the prolonged pharmacokinetics curves and pharmaceutic concentrations in tumor contributed to the inhibition of neovascularization that was proved with

Indexed as

68Ga-RGD PETcontrolled releaseneovascularizationnon-small cell lung cancerRecombinant human endostatin

Identifiers

PMID42787631
PMCPMC13601895

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.